Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: a randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussis
Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: a randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussis
Maheshi Ramasamy, Jonathan M Guy, Alison R Hill, Stephanie Noviello et al.
Citations
2 citations
Journal
The Lancet Microbe
Topics
Bacterial Infections and Vaccines
Field-Weighted Citation Impact (FWCI)
2.37
article
Efficacy, immunogenicity, and safety of the live attenuated nasal pertussis vaccine, BPZE1, in the UK: a randomised, placebo-controlled, phase 2b trial using a controlled human infection model with virulent Bordetella pertussis
Maheshi Ramasamy, Jonathan M Guy, Alison R Hill, Stephanie Noviello, Thomas Reed, Camille Locht, Peter A. Goldstein, Wei Lang, Lisa A. Weissfeld, Daniela M. Ferreira, Keith Rubin, Ken Solovay, Diane Gbesemete, Gavin Babbage, Saul N. Faust, Muktar Ibrahim, Adam P. Dale, Robert C. Read, Jay R. Laver, Vivek Samal, Lucy Raud, Tyween Coutinho
article en
2 citations
Abstract
No abstract available for this paper.
Publication Tag
The Lancet MicrobeVol. 6(12)
Institutions
Centre National de la Recherche Scientifique (FR), Inserm (FR), Institut Pasteur de Lille (FR), University Hospital Southampton NHS Foundation Trust (GB), Centre Hospitalier Universitaire de Lille (FR), Center for Infection and Immunity of Lille (FR), NIHR Southampton Biomedical Research Centre (GB), Oxford BioMedica (United Kingdom) (GB), Oxford University Hospitals NHS Trust (GB)